Anavex to present at Neuroscience 2012 in New Orleans
VANCOUVER, Oct. 12, 2012 /PRNewswire/ – Anavex Life Sciences Corp. (“Anavex”)
(OTCBB: AVXL) announces that new data on ANAVEX 2-73 will be presented
in a poster session at Neuroscience 2012 in New Orleans. ANAVEX 2-73
is the company’s lead compound for Alzheimer’s disease currently in
human clinical trials. Presentation details are as follows:
Date: Wednesday, October 17, 2012 Time: 3 p.m. to 4 p.m. Mitochondrial protection is induced by the novel Title: tetrahydrofuran derivative ANAVEX2-73 after ICV injection of oligomeric AÃŸ25-35 peptide in mice, a nontransgenic Alzheimer's disease model Poster #: 851.15
The abstract for this poster must remain confidential and cannot be
disclosed until the formal presentation has been made. Pursuant to
Society for Neuroscience policy, the poster and associated data may be
published following its presentation at Neuroscience 2012. Anavex will
publish the poster on its web site (anavex.com).
Any parties interested in meeting with the Anavex team at Neuroscience
2012 may contact the company’s communications team at +1 (416) 489-0092
Neuroscience 2012 takes place Saturday, October 13 to Wednesday, October
17, 2012 at the Ernest N. Morial Convention Center in New Orleans. It
is the premier venue for neuroscientists from around the world to debut
cutting-edge research on the brain and nervous system. Additional
information is available at http://www.sfn.org/am2012/home.aspx.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a pharmaceutical company engaged in the development of novel drug
candidates. Lead compound ANAVEX 2-73, developed to treat Alzheimer’s
through disease modification, is in human clinical trials. A Phase 1
single ascending dose study of ANAVEX 2-73 was successfully completed
in Germany in 2011. Studies indicate that ANAVEX 2-73 demonstrates
anti-amnesic and neuroprotective properties, and that it is well
tolerated in doses up to 55mg. The company is preparing to embark on a
multiple ascending dose clinical trial of ANAVEX 2-73 in 2012. Anavex
is a publicly traded corporation quoted as AVXL.
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in drug
discovery and development, which include, without limitation, the
potential failure of development candidates to advance through
preclinical studies or demonstrate safety and efficacy in clinical
testing and the ability to pass clinical trials so as to move on to the
next phase, our ability to finance development or satisfy the rigorous
regulatory requirements for new drugs, our ability to attract and
retain quality personnel, and that despite positive results, our
competitors may offer better or cheaper alternatives. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Anavex Life Sciences Corp. undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof.
Anavex Life Sciences Corp.
Research & Business Development
SOURCE Anavex Life Sciences Corp.